Clinical outcomes at 9–10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome

Documents similaires

• Treatment of small as well as large declines in lung function enhances recovery to baseline in people with CF
  par: Michael S. Schechter, et autres
  Publié: (2024)
• Adding fuel to the fire: The growing case for global access to cystic fibrosis transmembrane conductance regulator modulator therapy
  par: Brenda M. Morrow, et autres
  Publié: (2024)
• Lung T1 MRI assessments in children with mild cystic fibrosis lung disease
  par: Clement L. Ren, et autres
  Publié: (2024)
• Implementation and outcomes of a quality improvement project to systematically assess the gross motor skills in school‐aged children with cystic fibrosis
  par: Abby Good, et autres
  Publié: (2024)
• Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting
  par: Valeria Daccò, et autres
  Publié: (2024)